EMA Authorised: Lixiana (edoxaban tosilate) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

The EMA authorised Lixiana (edoxaban tosilate) from Daiichi Sankyo Europe GmbH for indications related to stroke and venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Venous Thromboembolism

Drugs mentioned

• Lixiana (edoxaban)

Snippet

Status: Authorised. Therapeutic area: Stroke;Venous Thromboembolism. MAH: Daiichi Sankyo Europe GmbH. Decision date: 24/07/2025